Evidence map›Paper›PMID 31832310›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2019

GLTSCR1 Negatively Regulates BRD4-Dependent Transcription Elongation and Inhibits CRC Metastasis.

Fengyan Han, Lei Zhang, Chaoyi Chen, Yan Wang, Yi Zhang, Lili Qian, Wenjie Sun, Dan Zhou, Beibei Yang, Honghe Zhang and 1 more

Open access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. BRD4 as a Therapeutic Target in Pulmonary Diseases.International journal of molecular sciences · 2023
    Review
  8. Article
  9. BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Fengyan HanDepartment of Pathology Key Laboratory of Disease Proteomics of Zhejiang Province Research unit of intelligence classification of tumor pathology and precision therapy Chinese Academy of Medical Sciences (2019RU042) School of Medicine Zhejiang University Hangzhou 310058 China.ORCID https://orcid.org/0000-0002-4633-7843
Lei ZhangDepartment of Pharmacology China Pharmaceutical University Nanjing 210009 China.
Chaoyi ChenDepartment of Pathology Key Laboratory of Disease Proteomics of Zhejiang Province Research unit of intelligence classification of tumor pathology and precision therapy Chinese Academy of Medical Sciences (2019RU042) School of Medicine Zhejiang University Hangzhou 310058 China.
Yan WangDepartment of Pathology Key Laboratory of Disease Proteomics of Zhejiang Province Research unit of intelligence classification of tumor pathology and precision therapy Chinese Academy of Medical Sciences (2019RU042) School of Medicine Zhejiang University Hangzhou 310058 China.
Yi ZhangDepartment of Pathology Key Laboratory of Disease Proteomics of Zhejiang Province Research unit of intelligence classification of tumor pathology and precision therapy Chinese Academy of Medical Sciences (2019RU042) School of Medicine Zhejiang University Hangzhou 310058 China.
Lili QianDepartment of Pathology Key Laboratory of Disease Proteomics of Zhejiang Province Research unit of intelligence classification of tumor pathology and precision therapy Chinese Academy of Medical Sciences (2019RU042) School of Medicine Zhejiang University Hangzhou 310058 China.
Wenjie SunDepartment of Pathology Key Laboratory of Disease Proteomics of Zhejiang Province Research unit of intelligence classification of tumor pathology and precision therapy Chinese Academy of Medical Sciences (2019RU042) School of Medicine Zhejiang University Hangzhou 310058 China.
Dan ZhouDepartment of Pathology Key Laboratory of Disease Proteomics of Zhejiang Province Research unit of intelligence classification of tumor pathology and precision therapy Chinese Academy of Medical Sciences (2019RU042) School of Medicine Zhejiang University Hangzhou 310058 China.
Beibei YangDepartment of Pathology Key Laboratory of Disease Proteomics of Zhejiang Province Research unit of intelligence classification of tumor pathology and precision therapy Chinese Academy of Medical Sciences (2019RU042) School of Medicine Zhejiang University Hangzhou 310058 China.
Honghe ZhangDepartment of Pathology Key Laboratory of Disease Proteomics of Zhejiang Province Research unit of intelligence classification of tumor pathology and precision therapy Chinese Academy of Medical Sciences (2019RU042) School of Medicine Zhejiang University Hangzhou 310058 China.ORCID https://orcid.org/0000-0001-5954-2857
Maode LaiDepartment of Pathology Key Laboratory of Disease Proteomics of Zhejiang Province Research unit of intelligence classification of tumor pathology and precision therapy Chinese Academy of Medical Sciences (2019RU042) School of Medicine Zhejiang University Hangzhou 310058 China.
Zhejiang Chinese Medical University · CNChina Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Frameshift mutations frequently occur in colorectal cancer (CRC) with microsatellite instability (MSI), but the nature and biological function of many MSI-associated mutations remain elusive. Here, an MSI frameshift mutation is identified in glioma tumor suppressor candidate region gene 1 (

Indexed as

frameshift mutationsglioma tumor suppressor candidate region gene 1 (GLTSCR1)microsatellite instability (MSI)transcription elongation

Identifiers

PMID31832310
PMCPMC6891902
OpenAlexW2981032926

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.